Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Status:
Terminated
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
Juvenile dermatomyositis (JDMS) is one of the most serious of the childhood rheumatic
diseases. The theory behind this trial is that early introduction of etanercept or
methotrexate will prove to be effective in the treatment of JDMS. Pretreatment muscle
biopsies, we believe there will be abnormalities in the blood vessels that will be correlated
with worse physical strength and daily functional ability. The long-term goal is to improve
the treatment of this serious childhood onset rheumatic disease and to better understand the
pathogenic mechanism for the development of the vasculopathy (disorder of blood vessels) of
JDMS. Identification of the specific mechanism of the vasculopathy may allow for the rational
introduction of biologic treatments focused on vascular growth.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
Immunex Corporation National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)